reaction rather than by a structural effect. On the other hand, Feld 230, 69120 (Brinkmann et al., 1993; Reiter et al., 1995 et al., 1993). Bispecific diabodies are heterodimers consisting have insufficient stability because the V H and V L domain of two scFv antibody fragments in which the V L and the V H can rapidly dissociate, which is usually accompanied by domains of the two Fv antibody fragments are present on aggregation (Glockshuber et al., 1994) . Therefore, different different polypeptide chains. The oligopeptide linkers between strategies have been developed to stabilize the association of these domains are too short to allow pairings between V H and these domains. The most widespread solution is to connect V L domains at the same chain (Perisic et al., 1994 ; Poljak, the V H and V L domain by a short peptide linker between the 1994). Diabodies have been employed in immunoassays carboxy-terminus of one domain and the amino-terminus of (Kontermann et al., 1997a; Watkins et al., 1999) or to recruit the other to form a single-chain Fv antibody fragment (scFv) C1q, resulting in efficient lysis of antigen-coated sheep erythro-(Bird et al
contact surface by a covalent connection instead of utilizing a stefan.duebel@urz.uni-heidelberg.de linker peptide. To achieve this, cysteine residues have been A bispecific disulfide-stabilized Fv antibody fragment genetically engineered into complementary framework posi-(dsFv-dsFvЈ) consisting of two different disulfide-stabilized tions of the V H and the V L domain distant from the CDRs to Fv antibody fragments connected by flexible linker peptides form disulfide bond-stabilized Fv antibody fragments (dsFvs) was produced by secretion of three polypeptide chains (Brinkmann et al., 1993; Reiter et al., 1995) . These molecules into the periplasm of Escherichia coli. The dsFv-dsFvЈ are very stable and usually retain full antigen binding activity. molecules were enriched by immobilized metal affinity Sometimes, they have even better antigen binding affinities chromatography and further purified by anion-exchange than their scFv homologs (Reiter et al., 1994a-c ; Webber chromatography. The recombinant antibody constructs et al., 1995) . retained the two parental antigen binding specificities and
In recent decades, recombinant antibody technologies were were able to cross-link the two different antigens. The developed which allow the addition of new functions to the described dsFv-dsFvЈ design might be of particular value antigen binding domains of immunoglobulin derivatives. The for therapeutic in vivo applications since improved stability production of various Fab, scFv or dsFv fusion proteins with is expected to be combined with minimal immunogenicity.
heterologous partners has been reported (Breitling and Dübel, Keywords: antibody engineering/bispecific antibodies/bivalent 2000). Further, homologous fusions, i.e. bispecific antibodies, antibodies/dsFv/recombinant antibodies allowed the cross-linking of two different antigens, e.g. on two different cells. These molecules are particularly useful to Abbreviations: Fv, antibody fragment consisting of the variredirect T-cells to tumor cells that are not originally recognized able region of light and heavy chain; V H , variable region of by the cellular immune system (Hombach et al., 1993 ; Arndt heavy chain; V L , variable region of light chain; dsFv, disulfideet al., 1999) . The application of hybrid hybridoma (quadroma) stabilized Fv antibody fragment; phOx, 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one technology initially developed to produce bispecific antibodies was hampered by problems of cell line stability, yield and purification of the desired antibody since the co-expression of two antibodies in one cell leads to the production of 10 Introduction different heavy and light chain combinations. Therefore, various recombinant approaches have been employed to generate The variable region (Fv) of an antibody, comprised of the bivalent and bispecific antibodies in heterologous expression variable heavy (V H ) and the variable light chain (V L ) domain, systems Kontermann, is the smallest antibody fragment containing a complete antigen 2000). Particularly promising is the diabody format (Holliger binding site. Many native Fv antibody fragments, however, et al., 1993) . Bispecific diabodies are heterodimers consisting have insufficient stability because the V H and V L domain of two scFv antibody fragments in which the V L and the V H can rapidly dissociate, which is usually accompanied by domains of the two Fv antibody fragments are present on aggregation (Glockshuber et al., 1994) . Therefore, different different polypeptide chains. The oligopeptide linkers between strategies have been developed to stabilize the association of these domains are too short to allow pairings between V H and these domains. The most widespread solution is to connect V L domains at the same chain (Perisic et al., 1994; Poljak, the V H and V L domain by a short peptide linker between the 1994). Diabodies have been employed in immunoassays carboxy-terminus of one domain and the amino-terminus of (Kontermann et al., 1997a; Watkins et al., 1999) or to recruit the other to form a single-chain Fv antibody fragment (scFv) C1q, resulting in efficient lysis of antigen-coated sheep erythro- (Bird et al., 1988; Huston et al., 1988; Whitlow and Fipula, cytes (Kontermann et al., 1997b) . Bispecific diabodies with 1991). In comparison with the much larger complete IgG, one arm directed against the target antigen and the other scFv antibody fragments have lower retention times in nonagainst the serum Ig were able to recruit complement, induce target tissues, a more rapid blood clearance and better tumor mononuclear phagocyte respiratory burst and phagocytosis and penetration in vivo (Milenic et al., 1991; Yokota et al., 1992;  promote synergistic cytotoxicity towards colon carcinoma cells Adams et al., 1993; Colcher et al., 1999) . They are therefore in conjunction with CD8ϩ T-cells (Holliger et al., 1997) . useful for some diagnostic and therapeutic applications, e.g.
Other diabodies have been used successfully to target directly for the targeted delivery of radionuclides, drugs or toxins to a tumor site. The improved stability of scFv antibody molecules cytotoxic T-cells to tumor markers, lymphoma cells or cytokine secreting cells in vitro (Holliger et al., 1996; Zhu et al., 1996;  Unwanted restriction sites for NcoI in the kanamycin resistant gene and MluI in the lac Iq gene of the resulting vector Helfrich et al., 1998; Krebs et al., 1998; Denton et al., 1999; Holliger et al., 1999) and in vivo (Arndt et al., 1999) . A major pDOPE51-215b were mutated which led to the vector pDOPE51-215(GS). To obtain pDOPE511-215, the dsFv(215) disadvantage of the diabody design is that the two antibody polypeptide chains are not covalently cross-linked. This facilitcoding region was cleaved out of pOPE511-215 with NcoI (New England Biolabs) and NotI and ligated to the vector fragment ates dissociation of the polypeptide chains followed by aggregation. Further, diabodies are usually not very flexible since they of pDOPE51-215(GS) cut with the same restriction enzymes. Finally, the vector pDOPE511-Cys(105)V H (phOx)/ have two linker peptides between the Fv fragments which have to be very short to prevent monomer formation. Some Cys(100)V L (215) was generated by introducing the Cys (105)V H (phOx) coding region from pOPE511-phOx into the diabody constructs lead to the formation of oligomers of higher valency (Kortt et al., 1997; Lawrence et al., 1998; Atwell plasmid pDOPE511-215 (FitzGerald et al., 1997) . These constructs, however, still required two short linker peptides. Recently, linker coding regions were generated by the synthesis of the overlapping oligonucleotide forward primers 5Ј-TCA GGT Bera et al. (1998) reported the production of a bivalent Fv immunotoxin based on the assembly of two polypeptides. In GGA GGC GGT TCA GGC GGA GGT GGC TCA GAT, 5Ј-TCA GGT GGA GGC GGT TCA GGC GGA GGT GAT, this construct, the V H and the V L domains of the anti-erbB2 antibody e23 were covalently linked to each other by a disulfide 5Ј-TCA GGT GGA GGC GGT TCA GAT or 5Ј-TCA GGT GGA GGC GAT and the reverse primers 5Ј-ATC TGA GCC bond. The two V H domains of the dsFvs are connected by a single flexible polypeptide linker. They further fused this ACC TCC GCC TGA ACC GCC TCC ACC, 5Ј-ATC ACC TCC GCC TGA ACC GCC TCC ACC, 5Ј-ATC TGA ACC GCC bivalent, but not bispecific (dsFv) 2 antibody molecule to PE38, a truncated form of Pseudomonas exotoxin, to generate a TCC ACC or 5Ј-ATC GCC TCC ACC, respectively. The corresponding oligonucleotides were phosphorylated, hybridized recombinant immunotoxin.
In this paper, we describe for the first time the construction and ligated to the vector pOPE101-Cys(44)V H (215)-YolCys(43)V L (phOx) digested with the restriction enzymes Bsu36I and functional expression of a bispecific dsFv-dsFvЈ construct, which was generated by connecting two disulfide-stabilized (New England Biolabs) and EcoRV. (215)-n-Cys(43)V L (phOx) (n ϭ 10, 8, All standard cloning procedures were carried out as described by Sambrook et al. (1989) . The construction of the vectors 5 or 3) were generated by introducing the Cys(44)V H (215)-nCys(43)V L (phOx) coding regions cleaved out of the plasmids pOPE51-215(GS), pOPE51b-215(Yol), pOPE101-215(Yol), pOPE511-215, pOPE111-215 and pOPE511-phOx has pOPE101-Cys(44)V H (215)-n-Cys(43)V L (phOx) (n ϭ 10, 8, 5 or 3) with the restriction enzymes EcoRI and BamHI (New been described previously (Kontermann et al., 1995; Schmiedl et al., 2000) . The vector pOPE51-Cys (44) The vector pDOPE511-Cys(105)V H (phOx)/Cys(100)V L (215) identified by colony lifts (Breitling and Dübel, 1997b) on Protran BA 85 nitrocellulose (0.45 mm, Schleicher und Schuell, was obtained in several steps. First, the plasmid pDMI.1 (Lanzer, 1988) was digested with HindIII (New England Biolabs), treated Dassel, Germany) after induction with 100 µM IPTG and immunostaining with mouse monoclonal antibody Myc1-9E10 with Klenow fragment (New England Biolabs) and ligated to the PCR product obtained from pOPE51-215(GS) using the (Calbiochem, Cambridge, UK). The correct insertion of each gene fragment in productive clones was confirmed by restricoligonucleotide primers 5Ј-GTA TCA CGA GGC CCT TTC and 5Ј-GGT CGA CGT TAA CCG ACA AAC AAC AGA TAA.
tion analysis and partial sequencing. The production of antibody constructs after induction with 20 µM IPTG (when using and 100 mM glucose and grown at 37°C to an OD 600 nm of 0.6. The promoters were induced by the addition of 100 µM pOPE vectors) or 100 µM (when using pDOPE vectors) for 3 h was confirmed by electrophoresis of total cell lysates on isopropyl-β-D-thiogalactopyranoside (IPTG). After an additional 3 h of shaking at room temperature, the bacteria were 12% polyacrylamide SDS gels followed by immunoblotting and by ELISA.
harvested by centrifugation at 5000 g for 10 min. The total cell lysate was analyzed by SDS-PAGE followed by immuno-SDS-PAGE and immunoblot analysis blotting using the mouse monoclonal antibody Myc1-9E10 SDS-PAGE was carried out according to Laemmli (1970) on for immunodetection. 12% polyacrylamide gels stained with Coomassie Brilliant Extraction of soluble Fv fragments from the periplasm Blue R250 (Serva, Heidelberg, Germany). Immunoblots were performed according to Towbin et al. (1980) . Unspecific
For the preparation of periplasmic extracts, the harvested bacteria were resuspended in 1/10 of the original culture antibody binding was blocked with 2% (w/v) skimmed milk powder (Oxoid, Basingstoke, UK) in PBS (137 mM NaCl, volume of spheroblast solution [50 mM Tris-HCl (pH 8.0), 20% (w/v) sucrose and 1 mM EDTA], left for 20 min on ice 3 mM KCl, 8 mM Na 2 HPO 4 , 1 mM KH 2 PO 4 , pH 7.3) containing 0.05% (v/v) Tween 20 (MPBST). The mouse with occasional shaking and harvested by centrifugation at 4°C and 6200 g for 10 min. The supernatant representing the monoclonal antibody Myc1-9E10 (Calbiochem) recognizing the c-myc-tag, the rat monoclonal antibody Yol1/34 (Harlan periplasmic enriched fraction was cleared by centrifugation at 4°C and 30 000 g for 30 min, dialyzed against PBS and used Sera-lab, Sussex, UK) recognizing the Yol-tag or a rabbit serum 'A' recognizing exclusively the processed N-terminus for functional studies in ELISA. The bacterial pellet was resuspended in 1/10 of the original culture volume of 5 mM of the V H domain were used as primary antibodies for immunodetection (1/1000 in MPBST). SubMgSO 4 and left for 20 min on ice with occasional shaking. After centrifugation at 4°C and 30 000 g for 30 min, the sequently, HRP-conjugated antibodies to mouse, rat or rabbit immunoglobulins (Dianova, Hamburg, Germany) were applied supernatant representing the osmotic shock fraction was also dialyzed against PBS. Figure 1 ) were diluted 2 ml bed volume per liter of original bacterial culture of chelating Sepharose ('fast flow' loaded with NiCl 2 ; Pharmacia, 1:20 into LB-medium containing 100 µg/ml of ampicillin (Biomol, Hamburg, Germany), 50 µg/ml of kanamycin (Serva) Uppsala, Sweden), was equilibrated with PBS containing 96-well Immuno Plates (MaxiSorp F96; Nunc) were coated overnight at 4°C with 0.1 µg of phoxylated BSA in 100 µl of extracts were pooled, adjusted to the same buffer composition 0.1 M NaHCO 3 buffer (pH 8.0) per well. Unspecific antibody and applied to the column. After subsequent washing with binding was blocked with 400 µl of MPBS for 6 h at room 10 bed volumes of PBS containing 10 mM imidazole, 1 M temperature. Volumes of 100 µl of fractions containing the NaCl (pH 7.5), 10 bed volumes of PBS containing 50 mM antibody fragments were added per well. HRP-labeled streptavimidazole, 1 M NaCl (pH 7.5) and a final washing step with idin [Amersham Pharmacia, Braunschweig, Germany; 8:1000 10 bed volumes of PBS, the proteins were eluted from the in PBS, 0.05% (v/v) Tween 20], which was pre-incubated column using an imidazole gradient from 50 to 500 mM in with 0.1 nM of a biotinylated 215 epitope peptide (biotin-PBS containing 1 M NaCl (pH 7.5) over 10 bed volumes and LPHFIKDDYGPESRGFVENSYLAGLTPSE), was used for with another 10 bed volumes of PBS containing 500 mM detection. Another biotinylated peptide (biotin-KESimidazole and 1 M NaCl (pH 7.5). Fractions were analyzed RAKKFQRQHMDEGEEF) served as a control. Biotinylated by SDS-PAGE followed by immunoblotting using mouse peptides were supplied by the central peptide synthesis facility monoclonal antibody Myc1-9E10 (Calbiochem). The Fv antiof the Zentrum für Molekulare Biologie, Heidelberg, Germany. body fragments were further purified by anion-exchange TMB was used for the detection of bound enzymatic activity. chromatography using Mono Q HR 5/5 (Amersham Pharmacia, Uppsala, Sweden). Protein-containing fractions obtained from IMAC were pooled, dialyzed against 30 mM Tris-HCl (pH 7.8) Results and applied to the column equilibrated with the same buffer.
Vector construction After washing the column with 5 ml of 30 mM Tris-HCl (pH We designed a compatible set of two E.coli vectors to allow 7.8), the antibody fragments were eluted from the column the production of three polypeptide chains necessary to form using a biphasic NaCl gradient in 30 mM Tris-HCl (pH 7.8) a bispecific disulfide-stabilized Fv-FvЈ antibody molecule increasing to 250 mM in 20 ml, then from 250 mM to 1 M (Figure 1 ). In the resulting molecule, the heavy and the light in 2 ml. For final elution, 5 ml of 1 M NaCl in 30 mM Trischain of each of the two different Fv fragments are expected HCl (pH 7.8) were applied. The fractions were analyzed to be connected to each other by an interdomain disulfide by SDS-PAGE followed by immunoblotting using mouse bond (see Figure 7 , bottom). monoclonal antibody Myc1-9E10 (Calbiochem). Total protein
The dsFv antibody fragments used in the construct were was determined photometrically using Bradford solution derived from the mouse monoclonal antibody clone 3 (Bio-Rad, Munich, Germany). The amount of the bispecific (ϭ mAb215) (Krämer et al., 1980; Kontermann et al., 1995) dsFv(215)-dsFv(phOx) antibody molecule was estimated from binding to the largest subunit of RNA polymerase II of SDS-PAGE.
Drosophila melanogaster and from an scFv antibody fragment ELISA specific for the hapten 2-phenyloxazolin-5-one (phOx), which To determine the antigen binding activity of the different was isolated from a phage antibody library and improved by constructs, 96-well Immuno Plates (MaxiSorp F96; Nunc, chain shuffling (Marks et al., 1992) . To avoid mispairings of Wiesbaden, Germany) were coated overnight at 4°C with the variable domains, we mutated two different pairs of 0.1 µg of antigen (215-epitope β-galactosidase fusion protein, conserved, complementary framework positions distant from control peptide β-galactosidase fusion protein, BSA or BSAthe CDRs for disulfide stabilization of the two different Fv phOx) in 100 µl of 0.1 M NaHCO 3 buffer (pH 8.0) per well.
fragments. The disulfide bond-stabilized Fv(215) antibody The β-galactosidase-215 epitope fusion protein is an E.coli fragment, dsFv(215), was generated by the mutations of the β-galactosidase extended by a peptide tag containing the 215 amino acid Ser(44)Cys of the V H and Ala(100)Cys of the V L epitope (Kontermann et al., 1995) . β-Galactosidase fused domain. The dsFv(phox) antibody fragment was obtained to another peptide tag served as a specificity control. The by introducing the mutations Lys(105)Cys into the V H and recombinant β-galactosidase fusion proteins were purified from Ala(43)Cys into the V L domain. Cloning, expression and E.coli inclusion bodies as described (Kontermann et al., 1995) . characterization of the two separate dsFv molecules have been Phoxylated BSA was prepared by incubating a 20-fold molar described previously (Schmiedl et al., 2000) . excess of 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one
To generate the bispecific antibody fragment, the heavy (phOx; Sigma, Deisenhofen, Germany) with BSA (Sigma) in chain of the dsFv(215) antibody fragment and the light chain 0.1 M NaCO 3 (pH 8.5) for 2 h. To remove uncoupled of the dsFv(phOx) antibody were genetically connected by 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, the reaction short sequences coding for a flexible polypeptide linker. To mixture was dialyzed twice against PBS. assess the effect of the linker length on the folding properties Unspecific antibody binding was blocked with 400 µl of of the complete molecule, we generated a set of vectors 2% (w/v) skimmed milk powder (Oxoid) in PBS (MPBS) for encoding bispecific dsFv(215)-dsFv(phOx) antibody con-6 h at room temperature. Volumes of 100 µl of extracts structs with linkers consisting of three, five, eight or 10 containing the antibody fragments were added per well. The amino acid residues (Figure 1 ). The gene encoding the mouse monoclonal antibody Myc1-9E10 (1:1000 in MPBST) Cys(44)V H (215) domain was connected to the gene for the was used for immunodetection. Subsequently, HRP-conjugated Cys(43)V L (phOx) domain by respective oligonucleotides and goat anti-mouse antibodies were applied (1:2000 in MPBST), cloned into the pDOPE vector, a derivative of pDMI.1 (Lanzer, before 3,3Ј,5,5Ј-tetramethylbenzidine (TMB; Sigma-Aldrich, 1988) . The genes encoding for the Cys(105)V H (phOx) domain Steinheim, Germany) was used for the detection of bound and the Cys(100)V L (215) domain were cloned into the expresenzymatic activity. The mouse monoclonal antibody ARNA3 sion vector pOPE111 (Schmiedl et al., 2000) . Each of the two (Progen, Heidelberg, Germany) recognizing the 215 peptide genes was separately cloned in-frame between a pelB-leader (Kontermann et al., 1995) was used as a positive control.
sequence (Lei et al., 1987) for the secretion of the antibody fragments into the periplasmic space and a small coding region To determine the bispecificity of the antibody constructs, for C-terminal tags facilitating detection and purification. In the correct cell compartment, reduced periplasmic extracts of induced and non-induced bacteria were analyzed on 12% case of the Cys(105)V H (phOx) domain, the tag contains polyacrylamide gels followed by immunoblotting (Figure 2 ). the linear epitope 'EEGEFSEAR' recognized by the mouse A significant amount of proteins could be detected utilizing monoclonal antibody mAb Yol1/34 (Kilmartin et al., 1982;  mAb Myc1-9E10 ( Figure 2B ) and serum 'A' (Figure 2C ), Breitling and Little, 1986) . At the C-terminus of both V L thus demonstrating the expression of the antibody components domains, a short peptide tag of the proto-oncogene product as soluble proteins in the periplasmic space. c-myc was located containing the linear epitope 'EEKLI-SEEDL' recognized by the mouse monoclonal antibody mAb Myc1-9E10 (Evan et al., 1985) followed by six histidine be produced in E.coli residues. The resulting vector pOPE111-V H (phOx)/V L (215) To check for a correct folding and assembly of all three and the set of four different variants of pDOPE101-V H (215)-polypeptide chains, separate binding studies by ELISA on n-V L (phOx) (n ϭ 10, 8, 5 or 3) encoding different linkers both antigens (215 epitope β-galactosidase fusion protein and between their variable heavy and light chain regions are shown phoxylated BSA) were performed. First, periplasmic extracts in Figure 1 . The two backbones encode for compatible origins of induced and non-induced cultures were prepared and subof replication and different resistance markers. A combination jected to antigen ELISA. Bound antibody fragments were of a pOPE and pDOPE vector can thus be propagated in the detected by their c-myc peptide tag. All dsFv fragments retained same E.coli cell after co-transfection.
Functional bispecific dsFv(215)-dsFv(phOx) molecules can
the antigen binding specificity of the original antibodies. To confirm the function of the individual vectors first, all ( Figure 3A) . The antibody construct containing the 10 amino plasmids were separately electrotransferred into E.coli XL1-acid residue linker showed the strongest binding activity to Blue competent cells. The production of the antibody componboth of the two antigens. ents after induction of their promoters with 100 µM IPTG To determine whether both antigen binding sites were present (when using the vector pDOPE101) or 20 µM IPTG (when within a single bispecific molecule, phoxylated BSA was using pOPE111) for 3 h was confirmed by electrophoresis of bound to ELISA wells and incubated with periplasmic extracts. total cell lysates on 12% polyacrylamide SDS gels followed Bound antibody fragments were detected with a small biotinylby immunoblotting using the mouse monoclonal antibody mAb ated peptide containing the 215-epitope, that was pre-incubated Myc1-9E10 for immunodetection (data not shown).
with HRP-labeled streptavidin. All of the four constructs provided bispecific binding activity. Again, the construct con-
Expression of the recombinant bispecific dsFv(215)-
taining the 10 amino acid residue linker showed the strongest dsFv(phOx) antibody construct antigen cross-linking activity ( Figure 3B ).
E.coli XL1-Blue competent cells were co-transfected with one
After proof of principle for the production of bispecific dsFvof the plasmid variants of pDOPE101-V H (215)-n-V L (phOx) dsFvЈ antibody molecules, the antibody construct containing the containing different linker lengths (n ϭ 10, 8, 5 or 3) and 10 amino acid residue linker was selected for further studies. pOPE111-V H (phOx)/V L (215) to express the three polypeptides Different IPTG concentrations were employed to determine required to form the bispecific disulfide bond-stabilized antithe optimum IPTG concentration for the production. The body construct within the same cell. The production of antibody highest amount of functional protein was obtained after inducfragments after induction with 100 µM IPTG for 3 h was tion with 100 µM IPTG as shown by ELISA (Figure 4 ). confirmed by electrophoresis of total cell lysates of induced Higher IPTG concentrations led to larger amounts of total and non-induced culture samples on 12% polyacrylamide SDS protein, but an increasing portion of the expressed antibody gels ( Figure 2A ) followed by immunoblotting using the mouse fragments still carried the leader sequence and formed aggregmonoclonal antibody Myc1-9E10 for immunodetection ates (data not shown). This observation is in good accordance ( Figure 2B ). After induction, the expected bands corresponding with results obtained for the production of scFv antibody to the processed translation product Cys(44)V H (215)-nfragments from a related vector . Cys(43)V L (phOx) (calculated molecular mass 27.4 kDa for Purification of dsFv(215)-dsFv(phOx) molecules n ϭ 10) as well as the processed translation product Cys(100)V L (215) (calculated molecular mass 14.8 kDa for Following these observations, the disulfide-stabilized, n ϭ 10) were detected. The two bands appear to be produced bispecific antibody construct containing the 10 amino acid in similar amounts as concluded from their almost identical residue linker was purified from the periplasm after induction intensities. The production of the Cys(105)V H (phOx) domain with optimized IPTG concentrations. As a first purification (calculated molecular mass 15.3 kDa) was confirmed by step, the antibody fragment was enriched from periplasmic immunoblotting using the rat monoclonal antibody Yol1/34 extracts by IMAC (Lilius et al., 1991) . The fractions contained (data not shown). To confirm the observations in respect of a significant amount of E.coli proteins. Therefore, they were the processing, immunoblots were further analyzed with rabbit further subjected to ion-exchange (Mono Q) chromatography serum 'A', which recognizes the sequence QVQLQ located at (Figures 5 and 6 ). the N-terminus of the V H (215) domain .
Seven peaks (A-G) were observed ( Figure 5A ) and the Serum 'A' does not react with QVQLQ when presented as an corresponding protein fractions were analyzed by electrophorinternal epitope and can therefore be used to confirm the esis on 12% polyacrylamide gels followed by immunoblotting proteolytic removal of the signal sequence from the antibody under reducing ( Figure 6A ) and non-reducing ( Figure 6B ) fragment. The V H domain of the phOx antibody fragment does conditions. The three components of the bispecific antibody not contain the QVQLQ epitope and could not be detected molecule with a calculated molecular mass of 57.5 kDa, namely in this approach. However, the expression and the correct the V H (215)-V L (phOx) linker construct, V L (215) domain and processing of a substantial fraction of the V H domain of the the V H (phOx) domain were detected by immunoblotting under dsFv 215 molecule could be confirmed ( Figure 2C ).
reducing conditions ( Figure 6A ). Under non-reducing conditions ( Figure 6B ), fractions 11 and 12 (peak D) contained a To confirm the production of soluble antibody fragments in The results demonstrate for the first time that three different construct. Fraction 11 contained also a significant amount of antibody domains can be covalently assembled to form a a 29 kDa protein, which is not the V H (215)-V L (phOx)-linkerfunctional molecule in the periplasm of E.coli. However, construct of pDOPE as determined under reducing conditions. careful balancing of the production rates of all three polypeptide This protein is potentially a dimer of the V L (215) domain and, chains is essential. Before we came to the final design of the since it is also present in fraction 10, we concluded that it did vectors as described in Figure 1 , we had generated a set of not contribute to the bispecificity demonstrated by ELISA vector derivatives with the respective antibody fragment ( Figure 5C ). The other peaks contained mainly 215 light chain coding inserts exchanged between the pOPE and pDOPE domains (peaks A, B and C) or contaminating E.coli proteins vectors. In these cases, however, the Cys(44)V H (215)-n-(peaks E, F and G). To determine the antigen binding activities Cys(43)V L (phOx) polypeptide chains were expressed to a of the different fractions, 100 µl samples were analyzed by higher amount in comparison with the Cys(100)V L (215) chains. single antigen as well as by cross-linking ELISA as described.
We obtained similar 215-epitope and phOx-binding activities In support of the immunoblot analysis, fractions 11 and 12 with crude periplasmic extracts but only a low antigen crosswere shown to contain the strongest antigen binding to the linking activity, indicating the prevalence of products with 215-antigen and to phoxylated BSA ( Figure 5B ), as well as only one correctly formed dsFv fragment. in the ELISA setup determining the antigen cross-linking Several approaches have been used previously to generate ( Figure 5C ). The yield of the bispecific antibody construct recombinant bivalent or multivalent Fv antibody molecules. was determined to be 0.1 µg/l of E.coli culture after purification.
The protein designs include disulfide-linked antibody fragments, mini-antibodies and diabodies (Cumber et al., 1992; Discussion Gruber et al., 1994; Hayden et al., 1994; De-Jonge et al., 1995; Holliger et al., 1996) . To produce bivalent Fab (Rodrigues et al., We constructed, produced and purified a new type of recombin-1993) or scFv molecules (Adams et al., 1993 (Adams et al., , 1995 ; McCartney ant bispecific antibody in which both V H /V L heterodimers et al., 1995) , an unpaired cysteine located at the C-terminus were stabilized by an interdomain disulfide bond. The V H of the antibody fragment has frequently been employed. domain of one dsFv molecule and the V L domain of the other dsFv fragment were cross-linked by a single, flexible
Oxidation led to the formation of an interdomain disulfide blood clearance. A similar approach to produce bispecific Antigen cross-linking activity was determined in a sandwich ELISA using miniantibodies was reported by Müller et al. (1998b) , who phoxylated BSA as antigen. Bound antibody contructs were detected with HRP-labeled streptavidin that was pre-incubated with the biotinylated 215-fused the C H 1 domain of an IgG 1 to an scFv fragment and the epitope peptide. A peptide comparable in size but not containing the 215-C L domain of a kappa light chain to another scFv fragment. epitope served as a specificity control.
The domain assembly led to a functional bivalent and bispecific mini-antibody.
Another strategy for the production of bispecific antibody bond between the two fragments, thus generating bivalent antibodies with enhanced affinity. However, the stability under molecules without fusion of the Fv fragment to heterologous domains is the production of scFv-scFvЈ antibodies ('tandem physiological conditions has not yet been assessed. Further, the unpaired cysteine led to problems with E.coli production antibodies') (Mallender et al., 1994a,b) . Two scFv molecules of different specificity were covalently cross-linked via a (Schmiedl et al., 2000) . To generate bivalent or multivalent Fv fusion proteins, a variety of self-associating secondary flexible polypeptide linker. These molecules were able to bind two adjacent epitopes on the same antigen (Neri et al., 1995) structures such as helix bundles, coiled coils or hybridizing oligonucleotides were further investigated (Pack and or cross-linking antigens on two different cells (Kurucz et al., 1995) . Of similar size but consisting of two separate polypep- Plückthun, 1992; Plückthun, 1992; Plückthun and Pack, 1997; Zahida et al., 1999) . Tetravalent mini-antibodies were designed tide chains is the diabody design with two antigen binding sites (Holliger et al., 1993) which can be bivalent or bispecific. by attaching the modified leucine zipper sequences at the carboxy-terminal end of scFv fragments via a hinge region or Bispecific diabodies are heterdimers of two 'cross-over' scFv fragments in which the V H and V L domains of the two parent by introducing a helical dimerization domain between two scFv fragments (Müller et al., 1998a) . Again, the stability of antibodies are present on different polypeptide chains. A potential disadvantage of this design is that the polypeptide these constructs under physiological conditions has not been reported and all constructs contained substantial heterologous linkers between these domains have to be shorter than in scFv fragments to prevent pairings between domains on the same domains that may give rise to an immune reaction against these domains which may interfere with therapeutic applications. The chain (Kortt et al., 1997) . High-level diabody secretion of functional diabodies from E.coli is possible, as demonstrated latter is to a much lesser extend expected from the minibody The antibody fragments were eluted from the column using a biphasic NaCl gradient in Fig. 6 . SDS-PAGE and immunoblot analysis of reduced (A) and non-30 mM Tris-HCl (pH 7.8) increasing to 250 mM in 20 ml, then from 250 reduced (B) fractions obtained after Mono Q chromatography. Total protein mM to 1 M in 2 ml. For final elution, 5 ml of 1 M NaCl in 30 mM Triswas stained with Commassie Brilliant Blue. MAb Myc1-9E10 was used for HCl (pH 7.8) were applied. The proteins were collected in 800 µl fractions immunodetection. using a flow-rate of 0.5 ml/min. (B) ELISA determining the binding to both antigens separately, as described in Figure 3 . (C) Antigen cross-linking ELISA as described in Figure 3. by the recovery of a humanized bispecific diabody in yields approaching 1 g/l (Zhu et al., 1996) and has been improved by domain interface engineering (Zhu et al., 1997) . Humanized or human diabodies pose little risk of immunogenecity since the only non-natural sequences are the short linkers between variable domains (Carter and Merchant, 1997) ; even these can be humanized by recruiting residues from the C L (Holliger et al., 1996) . The major disadvantage of both the tandem and the diabody design is that the domain interfaces of the two Fv fragments are not covalently cross-linked and thus prove the dissociation-related aggregation typical for all scFv derivatives. This problem has recently been addressed by the production of diabodies in which one Fv domain is disulfide stabilized (ds diabodies). These constructs confirmed the predictions obtained from monovalent dsFv fragments that a higher stability and improved tumor localization can be expected after disulfide stabilization (FitzGerald et al., 1997) .
In general, owing to the necessity to have two very short linkers between their variable domains, diabodies are ridgid and not very flexible, which may lower the chances of obtaining optimum binding to both antigens to be cross-linked in an in vivo situation. The new design described in this paper addresses this potential disadvantage, as well as the stability and immunogenicity issue, in trying to combine proven features of previous designs (Figure 7) . Therefore, the dsFv-dsFvЈ is
